Veracyte (VCYT) 10-K2023 FY Annual report

Filed: 29 Feb 24, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AI, Artera, Aviv, bankruptcy, bespoke, bioinformatic, biometric, broaden, buildout, carbon, Castration, certainty, chair, Chapter, CIO, Coleman, condensed, Counsel, CSE, Cyberspace, decentralized, declassified, Dignity, disaggregated, diversification, download, durable, duty, East, electricity, enterprise, ERM, ethical, farthest, flawed, forfeiture, gas, gasoline, GC, gradually, heading, house, inaugural, inorganically, insolvent, intrusion, Invitae, Israeli, keycard, Liberty, logging, ml, mobilization, Montana, MRD, multidisciplinary, Natera, NextSeq, NextSeqDx, NGS, NIGHTINGALE, nonqualified, onward, Oregon, overseeing, payor, phaseout, plant, plasma, polymerase, portal, PPL, proximity, qPCR, Quest, reaction, receivership, recertify, repository, residual, residue, Resistant, revisit, RSU, struggled, succeeding, successor, Tel, thousand, threat, threatened, tied, tranche, trust, tube, turbulence, turmoil, Twist, University, USPTO, violative, VP, water, withheld, workstation

Removed: accessible, Acerta, administer, annum, arise, arm, AstraZeneca, biorepository, bronchoscopy, canceled, CareDx, Codification, College, combat, conference, contact, deducted, deferring, deployment, determinable, distinguish, drop, earlier, efficacy, employ, enabled, evolve, excluding, feasible, feel, frequency, fusion, hematology, ill, incidence, inefficiently, insight, institution, institutional, Interbank, IPO, Johnson, kidney, lesser, LIBOR, library, loan, Locating, London, MAVIDx, mitigated, notoriously, NSO, plastic, positioned, precautionary, prepayment, prevented, publishing, radiological, rare, reluctance, remotely, repaid, reproducibility, revolving, scheduled, seamlessly, Silicon, simultaneously, situation, slowdown, speaker, spectrum, spread, subleased, succession, teleconferencing, truth, Valley, variant, VIE

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VCYT transcripts

VCYT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Veracyte, Inc. (the "Company") on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	February 29, 2024

		/s/ Rebecca Chambers
		Rebecca Chambers
		Chief Financial Officer
		(Principal Financial Officer)